Posted by Michael Wonder on 20 Jul 2021
Kyowa Kirin announces EU approval for the self administration of Crysvita (burosumab) to treat X-linked hypophosphataemia
19 July 2021 - An additional option is now available to healthcare professionals to meet the needs of X-linked hypophosphataemia patients and their carers.
Kyowa Kirin today announced that Crysvita (burosumab) has been approved for the option of self-administration in the European Union for the treatment of X-linked hypophosphataemia, a rare metabolic bone disease that impacts children and adults.
The approval means that some patients or carers may be suitable to administer Crysvita themselves, at the recommendation of the treating physician, in its licensed indication for the treatment of X-linked hypophosphataemia in children and adolescents aged 1 to 17 years with radiographic evidence of bone disease, and in adults.
